The prestigious annual meeting of the American Society of Clinical Oncology (ASCO) kicked off this weekend with the presentations by several drug and biotech majors of new data on their already marketed and investigational cancer products (see also separate story today on Avastin), including the following:
Germany’s Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) announced positive results from the Phase III DECISION trial investigating the use of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze